PHASE 1 FIRST-IN- HUMAN STUDY OF DALUTRAFUSP ALFA,
Cluster of differentiation (CD)73-adenosine and transforming growth factor (TGF)-β pathways are involved in abrogated antitumor immune responses and can lead to protumor conditions….
Archive for Publications
RARE SOLID AND CYSTIC PRESENTATION OF HEMANGIOPERICYTOMA/ SOLITARY FIBROUS TUMOR: A CASE REPORT
MANUFACTURING-DEPENDENT CHANGE IN BIOLOGICAL ACTIVITY OF THE TLR4 AGONIST GSK1795091
EFFECT OF PEVONEDISTAT, AN INVESTIGATIONAL NEDD8-ACTIVATING ENZYME INHIBITOR
NEW ENGLAND JOURNAL OF MEDICINE: ADAGRASIB WITH OR WITHOUT CETUXIMAB IN COLORECTAL CANCERWITH MUTATED KRAS G12C
See Mary Crowley featured in the New England Journal of Medicine.
A PHASE I, OPEN-LABEL, DOSE CONFIRMATION, ESCALATION, AND EXPANSION TRIAL OF BI 1810631
PILOT STUDY OF COMBINATION GEMOGENOVATUCEL-T (VIGIL) AND DURVALUMAB
Gemogenovatucel-T (Vigil) is a triple-function autologous tumor cell immunotherapy which expresses granulocyte-macrophage colony-stimulating factor and decreases expression of…
PHASE 1/2 STUDY OF EPACADOSTAT IN COMBINATION WITH DURVALUMAB IN PATIENTS WITH METASTATIC SOLID TUMORS
BETA PRIME: PHASE I STUDY OF ADAPT-001 AS MONOTHERAPY
BETA PRIME, a phase I clinical trial, will study AdAPT-001, an oncolytic adenovirus that carries a TGF-β ‘trap’ +/- a checkpoint inhibitor with the ultimate objective to turn ‘cold’ tumors ‘hot’ and increase response rates.
FIRST-IN-HUMAN PHASE I/IB DOSE-FINDING STUDY OF ADAGRASIB (MRTX849) IN PATIENTS
Adagrasib (MRTX849) is an oral, highly selective, small-molecule, covalent inhibitor of KRASG12C…